Aster DM Healthcare rallied 7.23% to Rs 431.40 after the company reported consolidated net profit of Rs 96.84 crore in Q2 FY25 as compared with net loss of Rs 30.80 crore posted in Q2 FY24.
Bypolls: BJP names Karilal Nanoma its candidate for Rajasthan’s Chorasi seat (24-10-2024)
The BJP declared Karilal Nanoma as its candidate for the Chorasi assembly bypoll in Rajasthan. The announcement completes the party’s candidate list for the seven assembly seats bypolls scheduled on November 23. Other candidates include Jagmohan Meena, Rajendra Bhambhu, Sukhwant Singh, Rajendra Gurjar, Revant Ram Danga, and Shanta Devi Meena.
Shares of Federal Bank rise as Nifty drops (24-10-2024)
On the technical charts, the 200-day moving average of the stock stood at Rs 171.22.
CARE Ratings Ltd leads gainers in ‘A’ group (24-10-2024)
Piramal Pharma Ltd, Amber Enterprises India Ltd, Sona BLW Precision Forgings Ltd and Aster DM Healthcare Ltd are among the other gainers in the BSE’s ‘A’ group today, 24 October 2024.
Currency in circulation rises 6.5% on year (24-10-2024)
Powered by Capital Market – Live News
LTIMindtree shares gain 0.71% as Sensex falls (24-10-2024)
A total of 1,577 shares changed hands on the counter till 11:55AM (IST)
Sandur Manganese (24-10-2024)
A good article to know about Arjas steel’s business and both past as well as expected revenue:
Arjas’s PnL synopsis from a rating agency’s report dated May 31, 2024 (link):
@yogansh:
1- Would appreciate if you could share your views on how the Arjas acquisition by Sandur changes the profitability more than sum of the parts. IMO, paid amount seems to be slightly above par (from EV/EBITDA perspective) when compared to Tata Steel and JSW Steel.
2- How the balanc sheet will evolve post acquisition? I see they intend to do a QIP of 1000 Cr. ; proposed NCD of 450Cr. ; and Proposed Term Loan of 1200Cr.
Aurionpro up 3% on bagging multi mn dollar deal from bank in South Asia (24-10-2024)
Aurionpro’s iCashpro+ offers advanced cash management features such as digital payments, virtual accounts, and liquidity management, enabling transaction efficiency and providing real-time insights
Dinshaw Irani’s top sectoral picks for next market cycle (24-10-2024)
And obviously the US facing pharma, if you take a Trump call, there is definitely going to be a pressure going forward as such, so that is why we do not like the US focused pharma companies much and we do not have much exposure there, rather no exposure there as such. We are more focused on to domestic pharma. In a diagnostic space, we got the best player, the top player with us.